We serve 1-(2-Hydroxyethyl)-4-methylpiperazine CAS:5464-12-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(2-Hydroxyethyl)-4-methylpiperazine
CAS.NO:5464-12-0
Molecular Formula: C7H16N2O
Molecular Weight: 144.21500
Synonyms:
2-(4-methylpiperazin-1-yl)ethanol
Physical and Chemical Properties:
Density: 1.003 g / cm3
Boiling point: 54-55 ° C / 0.5mbar
Melting point: 39-41 ° C
Flash point: 106.1ºC
Refractive index: 1.485
Specification:
Appearance:White powder
Purity:≥97.0%
Impurity: ≤0.03
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.
Contact us for information like 1-(2-Hydroxyethyl)-4-methylpiperazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-methylpiperazin-1-yl)ethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-methylpiperazin-1-yl)ethanol Use and application,1-(2-Hydroxyethyl)-4-methylpiperazine technical grade,usp/ep/jp grade.
Related News: Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.2-Fluoro-5-iodobenzoic acid manufacturer Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.2,2-Diethoxytriethylamine supplier On Friday, US Health and Human Services Secretary Alex Azar declared the 2019 novel coronavirus a public health emergency and ordered any US citizens returning from the center of the outbreak in China to be quarantined for two weeks as a precaution.prop-2-yn-1-ol vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.
